3 results
Approved WMOCompleted
The purpose of this study is to obtain blood samples from up to 14 subjects who previously received namilumab in the previous study M1-1188-002-EM (PRIORA, [NCT01317797]) to correlate genetic markers with clinical outcomes.
Approved WMOCompleted
Primary: (part 3) Potential of BPR277 1% ointment b.i.d. to improve the clinical severity of lesional skin in the majority of NS patients at end of treatment versus baseline of >= 2 points, dose range and regimen relationship on clinical…
Approved WMOWill not start
The aim of the POLO study is to evaluate pharmacokinetics and safety of a single-dose of dolutegravir in patients with severe hepatic impairment (Child-Pugh score * 10) and compare these to matched controls.